On 27 January 2003, Cyclacel Limited, the UK-based biopharmaceutical
company, announced the appointment of Professor Karol Sikora to its
Oncology Scientific Advisory Board.
When the Human Genome Project comes to fruition, it will give us a tremendous amount of information. We will be able to predict high risk people - everyone will have a simple blood test and then we would be able to stop giving mammograms to many women.
